A cohort of fibromyalgia (FM) patients (n =90) and healthy controls (HC) (n= 93) was recruited to investigate the associations between human IgG binding to satellite glia cells (SGC) from dorsal root ganglia (DRG) and pathophysiological mechanisms. The study is based on previously identified mechanisms resulting from injecting human IgG antibodies from FM patients, but not HC, in mice (Goebel et al. J Clin Invest. 2021;131(13):e144201). Subjects have been carefully phenotyped using validated questionnaires and quantitative sensory testing (QST) was applied to determine pain sensitivity. A blood sample was taken to quantify anti-SGC IgG, as well as proteins, lipids and metabolites. Skin biopsies were taken to analyze changes in skin innervation (IENFD) and immune cell activation. Magnetic resonance spectroscopy (MRS) and functional magnetic resonance imaging (fMRI) was performed (n=122) to investigate central nervous system pain related mechanisms. Insular glutamate levels, as well as the levels of other brain metabolites will be determined (MRS) and related to symptom severity and anti-SGC IgG levels. Resting state as well as pain related cerebral activation (BOLD) during standardized evoked pain stimuli will be characterized (fMRI) and related to the MRS findings and to anti-SGC IgG levels.
Age range
20 Years – 65 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Group differences in anti-SGC IgG levels
Timeframe: 2 years
Resting state cerebral activity and anti-SGC IgG levels in FM
Timeframe: 2 years
Cerebral activation during pressure pain (150kPa) and anti-SGC IgG levels in FM
Timeframe: 2 years
Cerebral activation during pressure pain (300kPa) and anti-SGC IgG levels in FM
Timeframe: 2 years
Glutamate concentrations in anterior insula and anti-SGC IgG levels in FM
Timeframe: 2 years
Glutamate concentrations in posterior insula and anti-SGC IgG levels in FM
Timeframe: 2 years
Cerebral metabolites in anterior insula and anti-SGC IgG levels in FM
Timeframe: 2 years
Cerebral metabolites in posterior insula and anti-SGC IgG levels in FM
Timeframe: 2 years